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Background. Our T-PEMF trial has been revisited with focus on the pharmacopsychometric triangle in which eﬀect size is used
whencomparingwantedversusunwantedclinicaleﬀectsandqualityoflifeasoutcomes.Inthisanalysis,wehaveespeciallyfocused
on the self-reported HAM-D6. Methods. The antidepressive medication which the patients were resistant to was kept unchanged
during the ﬁve weeks of active versus sham T-PEMF. Results. In total 21, patients received active T-PEMF, and 19 patients received
sham T-PEMF. The eﬀect size was 1.02 and 0.90, respectively, on HAM-D6 and HAM-D6-S. Concerning side eﬀects, the active T-
PEMF reduced the baseline score on concentration problems with an eﬀect size of 0.44 while inducing more autonomic symptoms
than sham T-PEMF with an eﬀect size of −0.41. The advantage of active over sham T-PEMF obtained an eﬀect size of 0.48.
Conclusion. Active T-PEMF was found superior to sham T-PEMF within the pharmacopsychometric triangle with a clinically
signiﬁcant eﬀect size level above 0.40.
1.Introduction
In our trials on the concomitant use of repetitive transcra-
nial magnetic stimulation (rTMS) or transcranial pulsed
electromagnetic ﬁelds (T-PEMF) and antidepressants in
patients with treatment-resistant depression [1–3], we have
focussedontheclinician-administrateddepressionscales,for
example, the Hamilton depression scale (HAM-D17) or the
Montgomery-˚ Asberg depression scale (MADRS).
Over the last decade-patient-reported depression scales
have been found important as a supplemental assessment
of outcome in trials of antidepressants [4–6]. Moreover,
the pharmacopsychometric triangle has been introduced to
give an overall clinical outcome proﬁle of an intervention
[7, 8], taking into account the wanted antidepressive eﬀect,
the unwanted side eﬀects, and the patients’ own balanced
evaluation of health-related quality of life. The pharma-
copsychometric triangle is scientiﬁcally connected to eﬀect
size statistics [9, 10], as it allows us to evaluate diverse
outcome scales (wanted versus unwanted eﬀect as well as
subjective quality of life) by reference to an integrated unit,
namely, the standard deviation of the improvement scores
[7].
In our T-PEMF study [2], we included the patient-
reportedHAM-D6-S[5]justafterthistrialwasstarted.Thus,
40 out of the 50 original patients included in the analysis
reported here have completed the patient-administrated
HAM-D6-S.
The objective of this study was to revisit the T-PEMF
s t u d yb yM a r t i n ye ta l .[ 2] with focus on the 40 patients who
had completed the HAM-D6-S and to compare the results,
on the one hand, with the clinician-administrated HAM-D62 Depression Research and Treatment
for evaluation of the pure antidepressive outcome and, on
the other hand, to use the pharmacopsychometric triangle
and the related eﬀect size statistics, as the WHO-5 well-being
index [10] was included as a measure of quality of life. As
for side eﬀects evaluation, the UKU scale was reanalysed
[11].
2. Methods
2.1. Ethics. The study [2] was approved by the Committee
on Biomedical Research Ethics and the Danish Central Data
Register. Patients were given information as requested by the
Biomedical Research Ethics, and the patients all signed an
informed consent form.
The study was performed according to the Declaration of
Helsinki and the European Union Directive of Good Clinical
Practice [12] and was monitored by an external contract
company (Encorium, Denmark).
2.2. Patients. In total, 40 patients (12 males and 28 females)
with treatment resistant depression were included in the T-
PEMF revisited study. In total, 21 of these patients received
active T-PEMF, and 19 patients received sham PEMF. The
patients were diagnosed as having major depression accord-
ing to DSM-IV and treatment resistance with a required
score of 3 or more on the Sackeim scale [13].
2.3. Psychopharmacological Treatment. The psychopharma-
cological treatment for depression (antidepressants and
mood stabilizers), to which the patients had developed
resistance, was kept unchanged during the 4 weeks preceding
baseline and was maintained at the same dose level through-
out the study. However, zopiclone was permitted to treat
emergent sleep problems. Otherwise, no other change in
ongoing psychopharmacological treatment was allowed.
Most of the patients received more than one antide-
pressant (escitalopram, other SSRIs, and dual active antide-
pressants (venlafaxine, duloxetine, and mirtazapine) and
tricyclics. Moreover, 7.5% received lithium and 20% received
anticonvulsants as mood-stabilising drugs.
2.4. Psychometrics
2.4.1. Diagnosis. The DSM-IV diagnosis of major depression
was assessed by use of the MINI International Neuropsychi-
atric Interview (MINI) [14].
2.4.2. Clinician Administered Depression Rating Scales. The
HamiltonDepressionScale(HAM-D)wasusedintheHAM-
D17 version accepted by Hamilton [15]. The HAM-D6
version includes the six depression items found clinically
valid [16] and psychometrically valid [17] when measuring
the pure antidepressive eﬀect of a drug [18]. These six items
are depressed mood, guilt feelings, work and interests, psy-
chomotor retardation, psychic anxiety, and general somatic
(tiredness and/or pains). The patient-administrated HAM-
D6-S is the pencil-and-paper version released by Bech et al.
[5].
The theoretical score range of the HAM-D17 goes from 0
to 52, whereas the theoretical score range of HAM-D6 goes
f r o m0t o2 2 .
The melancholia scale (MES) is an eleven item version
based on the HAM-D6. It has also been found both clinically
and psychometrically valid when measuring the severity of
depressive states [19, 20].
The theoretical score range of MES goes from 0 to 44.
2.4.3. Patient-Rated Depression Scales. Both the self-rated
version of HAM-D6 (see above) and the major depression
inventory (MDI) [21]w e r eu s e d .
The MDI covers the items within the DSM-IV concept
of major depression, and its total score has been found
psychometrically valid. The theoretical score range of MDI
g o e sf r o m0t o5 0 .
2.4.4. Clinician Administered Side Eﬀect Scale. From the
UKU (Udvalg for Kliniske Undersøgelser, Committee for
Clinical Trials) [11], the 24 items for antidepressants [22]
were included. These 24 items consist of 10 items capturing
psychic side eﬀects (e.g., concentration disturbances or sleep
problems), 2 items covering neurological side eﬀects (e.g.,
tremor),8itemscoveringautonomicanxietysymptoms(e.g.,
nausea,constipation,diarrhoea,andincreasedsweating)and
6 items covering such symptoms as weight gain, headache,
and sexual dysfunction.
The theoretical score range of the UKU-24 in its original
version goes from 0 to 72, as each item is scored on a Likert
scalefrom0(notpresent)to3(severelytoextremelypresent)
[22]. However, in this study, the patients were expected to
be characterized by having a “tolerable” side eﬀects proﬁle
at the time of randomization (baseline), implying that the
score on each UKU-24 item goes from 0 (not present) to 1
(clearly present), but not interfering with daily functioning.
The theoretical score range is consequently from 0 to 24.
2.4.5. Quality of Life Scale. The WHO-ﬁve well-being index
was used. This scale contains ﬁve items covering psychologi-
cal well-being. The total score range goes from 0 (lowest level
of well-being) to 100 (highest level of well-being) [10].
2.4.6. T-PEMF Procedure. The T-PEMF procedure has been
described elsewhere in detail [2]. In brief, the T-PEMF
delivery system consists of a 220V pulse generator, which
provides pulses to the applicator constructed as a treatment
helmet. The dimensions of the Re5 T-PEMF generator are
(width × height × depth) 2.8 × 1.6 × 9.2 inches. The pulses
provided by the generator to the coils in the helmet alternate
between +50 and −50V. The treatment helmet incorporates,
on the inner side, 2 coils in the anterior and posterior
temporalregiononbothsidesand1coilintheupperparietal
region on both sides and 1 coil in the centre of the lower
occipital region. Thus, in total, 7 coils are connected in
parallel with the pulse generator. The Re5 T-PEMF pulse
generator powers the helmet with alternating bipolar square
pulses each lasting 3ms and interspersed by a 12ms pause,
each pulse sequence thus lasting 18ms, corresponding to a
pulse frequency of 55Hz. The rapid change of the currentDepression Research and Treatment 3
Table 1: Baseline characteristics.
Baseline characteristics
T-PEMF
Active Sham All
(N = 21) (N = 19) (N = 40)
Age, mean (sd) [range, years] 58.2 (12.9)∗ [35–85] 49.5 (11.9) [24–70] 54.0 (13.0) [24–85]
Duration of episodes (month)mean (sd) 2.2 (2.5) 3.2 (5.0) 2.7 (4.1)
% females 66.7% 63.2% 65.0%
∗P ≤ .05.
Table 2: Side eﬀects as total scores on UKU-24. LOCF analysis.
UKU-24 Active T-PEMF Sham T-PEMF
(N = 21) (N = 19)
Baseline 12.3 (2.6) 13.5 (2.3)
week 1 11.4 (3.4) 12.2 (2.7)
week 2 10.0 (3.4) 11.2 (2.9)
week 3 9.7 (3.1) 11.1 (2.4)
week 4 9.0 (3.0) 9.8 (2.1)
week 5 8.6 (3.8) 10.2 (2.3)
in the coils from the pulse generator creates an alternating
magnetic ﬁeld capable of inducing electrical ﬁelds in tissue
with an intensity of 2.5mV/cm at 2cms from the individual
coil [23].
In comparison, the depolarization (35mV) required
for induction of an action potential by opening of Na+
channelsovera10nmwideplasmamembraneisintheorder
of 3.5·106 V/m or 3.5·107 mV/cm and is, therefore, many
orders of magnitude larger than the electrical ﬁeld imposed
by the T-PEMF treatment (2.5mV/cm). In addition, the
ﬁelds in the human cortex induced by the T-PEMF system
are very much lower than those applied by rTMS equipment,
which uses stimuli approaching neuronal ﬁring level.
Patients came for daily sessions on all weekdays
(Monday–Friday) for 5 weeks at the two including centres.
Treatment was supervised to secure an accurate activation of
the generator and compliance with the 30 minute session.
2.4.7. Statistical Analysis. Eﬀect size was used to compare
active T-PEMF with sham T-PEMF. The standardized eﬀect
size was calculated using the last observation carried forward
(LOCF) approach for missing values. The standardized eﬀect
size is a descriptive statistic and is deﬁned as the diﬀerence
in mean change score from baseline to study endpoint
between active T-PEMF and sham T-PEMF divided by the
pooledstandarddeviation[24].Whenthediﬀerenceinmean
score from baseline to endpoint is positive, the eﬀect size is
positive, indicating in the HAM-D6 score for example that
active PEMF is superior to sham PEMF as a decrease in
the symptom score reﬂects an antidepressive eﬀect. For the
WHO-5 well-being index, in which an increase in total score
reﬂects greater well-being, the diﬀerence in mean score from
baseline to endpoint is negative if active PEMF is superior to
sham PEMF, resulting in a negative eﬀect size.
Cohen [9]c o n s i d e r e da ne ﬀect size of 0.50 to be
of clinical signiﬁcance, but in placebo-controlled clinical
trials of antidepressants in nontreatment resistant depressed
patients, an eﬀect size of 0.40 or higher is considered
clinically signiﬁcant [18] which is in agreement with Baer
and Blais [25].
3. Results
Out of the 40 patients included in the study, ﬁve patients
dropped out before the planned duration of the trial
period. Four of these patients received active T-PEMF, and
one received sham T-PEMF. Among the patients receiving
active T-PEMF, one patient dropped out due to change in
the antidepressive medication, one patient due to lack of
improvement, one patient did not wish to continue, and
one patient stopped due to vacation. The patient dropping
out in the sham T-PEMF group did so due to change in
antidepressive medication.
Table 1 shows the baseline characteristics of all 40
patients together and when subdivided into the 21 patients
receiving active T-PEMF and the 19 patients receiving
sham T-PEMF. No statistically signiﬁcant diﬀerences were
observed apart from age, as the active T-PEMF group of
patients was older than the sham group (58.2 versus 49.5
years of age (P ≤ .05)).
Figure 1 shows the pharmacopsychometric triangle in
which the pure antidepressive eﬀect is based on the
HAM-D17 and MES and on the clinician- versus patient-
administrated HAM-D6-S as well as on the self-rated MDI.
In general, the clinician-administrated scales (MES, HAM-
D17, and HAM-D6) obtained higher eﬀect sizes than the
patient-administrated scales (HAM-D6-S and MDI), but all
the eﬀe c ts i z e sw e r ea b o v e0 . 5 0 .T h es i d ee ﬀects as measured
by the clinician-administrated UKU-24 showed an eﬀect size
of 0.09.
As expected, the patients typically had at randomisation
a score range on the individual UKU items from 0 (not
present) to 1 (clearly present but not interfering with daily
functioning).However,forthepsychicUKUside-eﬀectitems
such as “concentration diﬃculties”, “tension/inner unrest”,
and “increased dream activity”, the score range lay between 0
and 2 (clearly present but without inﬂuencing patient’s daily
life to any marked degree).
Table 2 shows the total scores on the UKU-24 at baseline
(randomisation) and each week during the ﬁve weeks of
treatment. At baseline, the total score was approximately 12,
and it decreased during the ﬁve weeks of therapy in both
groups of treatment with, however, the numerically greatest
decrease in the active T-PEMF group of patients. Therefore,4 Depression Research and Treatment
Table 3: Comparison of clinician-rated and patient-rated HAM-D6. LOCF analysis.
HAM-D6
Clinician Patient
Active T-PEMF Sham T-PEMF Active T-PEMF Sham T-PEMF
(N = 21) (N = 19) (N = 21) (N = 19)
Baseline 12.5 (2.1) 12.5 (2.0) 13.9 (2.2) 13.8 (2.5)
week 1 10.6 (2.9)∗ 11.7 (2.1) 10.9 (3.8) 11.2 (3.3)
week 2 9.7 (2.2)∗ 10.6 (2.8) 9.3 (3.0)∗ 11.5 (4.4)
week 3 8.8 (2.3)∗ 10.6 (3.1) 8.6 (3.4)∗∗ 11.9 (4.0)
week 4 7.9 (3.0)∗ 10.8 (2.8) 7.8 (3.3)∗∗ 12.0 (4.0)
week 5 6.9 (3.7)∗ 10.5 (3.2) 7.0 (4.5)∗∗ 10.8 (3.7)
∗P ≤ .05.
∗∗P ≤ .01.
Table 4: The LOCF analysis with HAM-D17.
HAM-D17
Active T-PEMF Sham T-PEMF
(N = 21) (N = 19)
Baseline 21.29 (4.0) 21.62 (3.6)
week 1 17.33 (5.1)∗ 19.58 (3.3)
week 2 15.05 (3.2)∗ 17.63 (4.9)
week 3 14.10 (4.5)∗∗ 17.68 (4.9)
week 4 12.67 (5.6)∗∗ 17.79 (4.0)
week 5 11.38 (6.5)∗∗ 16.68 (4.4)
∗P ≤ .05.
∗∗P ≤ .01.
the eﬀect size of 0.09 is positive. In Figure 1,w eh a v ea l s o
indicated the eﬀect size for the UKU subscales of psychic,
neurological, autonomic, and other symptoms. For the UKU
subscale of psychic problems, the eﬀect size was 0.25. Within
these symptoms the item of concentration disturbances
obtained an eﬀect size above 0.40, indicating that these
symptoms achieved a better improvement on active than on
sham T-PEMF. As regards the UKU subscale of autonomic
symptoms, the eﬀect size was −0.41, indicating that these
symptoms reached a better improvement on sham T-PEMF
than on active T-PEMF. Within the autonomic symptoms,
the item of diarrhoea obtained an eﬀect size of −0.58.
OntheMESitemofconcentrationdisturbancestheeﬀect
size was 0.50.
With regard to the WHO-5 well-being index, higher
scores reﬂect higher quality of life explaining the negative
eﬀect size sign of −0.48 (Figure 1) to illustrate the advantage
of active T-PEMF over sham T-PEMF.
Table 3 shows the week-to-week scores on the HAM-
D6 clinician version when compared to the patient-
administrated HAM-D6-S. In general, the standard devia-
tions were numerically higher in the patient-administrated
version of HAM-D6 compared to the corresponding scores
on the clinician-administrated version. On the clinician
HAM-D6, thediﬀerencebetweenactiveversusshamT-PEMF
was statistically signiﬁcant as early as after one week of
therapy (P ≤ .05). However, on the patient-administrated
Table 5: The LOCF analysis with MES.
HAM-D17
Active T-PEMF Sham T-PEMF
(N = 21) (N = 19)
Baseline 21.62 (3.1) 21.21 (2.7)
week 1 17.90 (5.0)∗∗ 20.00 (3.5)
week 2 16.33 (3.2)∗ 18.68 (4.2)
week 3 14.95 (4.0)∗∗ 18.74 (4.5)
week 4 13.05 (5.1)∗∗ 18.16 (4.8)
week 5 11.90 (5.9)∗∗ 17.79 (4.7)
∗P ≤ .05.
∗∗P ≤ .01.
HAM-D6-S, the level of statistical signiﬁcance after 3 weeks
of therapy was greater (P ≤ .01) than on the corresponding
clinician HAM-D6 (P ≤ .05).
On the MDI (data not shown) the diﬀerence between
active and sham T-PEMF was ﬁrst seen after 4 weeks of
therapy at a level of signiﬁcance of P ≤ .05.
Table 4 shows the LOCF analysis for the HAM-D17, and
Table 5 showstheLOCFanalysisforMES.Forbothscales,the
diﬀerence between active and sham T-PEMF was statistically
signiﬁcant already after the ﬁrst week of treatment.
4. Discussion
As in our previous study [8], the pharmacopsychometric
triangle was found to have a high degree of communicative
validity. The eﬀect size statistics when comparing active T-
PEMF with sham T-PEMF clearly indicated the superiority
of the active T-PEMF in terms of antidepressive eﬀect and
the patients’ self-reported quality of life.
According to the most recent updating of the standard-
ization of Cohen’s eﬀect size statistics [25]i nr e l a t i o nt o
clinically signiﬁcant eﬀects, the interval between 0.00 and
0.19 refers to no eﬀect; 0.20 and 0.39 refers to a small
eﬀect; the interval between 0.40 and 0.69 refers to a medium
eﬀect; the level of 0.70 or higher refers to a large eﬀect. Our
pharmacopsychometric triangle which is linked to Cohen’s
eﬀect size statistics showed a large clinically signiﬁcant eﬀectDepression Research and Treatment 5
The pharmacopsychometric triangle
ﬀe e ct size calculation using the LOCF approach
Antidepressive eﬀect
LOCF approach
Side eﬀects
LOCF approach
Scales Scale
Scale
Eﬀect size Eﬀect size
HAM-D17 0.91 UKU-24 total 0.09
MES 1.22 Psychic 0.25
HAM-D6-C 1.02
C
B A
Concentration problems 0.44
HAM-D6-S 0.90 Neurological subscale 0.25
MDI 0.73 Autonomic subscale −0.41
Diarrhoea −0.58
Other problems
Quality of life
LOCF approach
Eﬀect
size
WHO-5 −0.48
0.30
Figure 1
with regard to antidepressive eﬀect, both on the clinician-
rated outcome scale and on the patient-rated scales.
The self-rating HAM-D6-S obtained an eﬀect size in
favour of active T-PEMF of 0.90, that is, as high as for
HAM-D17.
As regards the side eﬀects of the combination of antide-
pressive maintenance therapy and T-PEMF, the baseline
UKU scores decreased in both active and sham T-PEMF
group of patients. The decrease in the UKU symptom of
concentration disturbances was much higher in the active
T-PEMF-treated patients resulting in an eﬀect size of 0.44,
that is, medium eﬀect clinically. This was parallel to the
MES item of concentration disturbances with an eﬀect size
of 0.50. In other words, concentration disturbances seem to
be an important featureof the therapy-resistant patients; this
is in agreement with our principal component analysis of
the Montgomery-˚ Asberg depression scale (MADRS) and the
MES [3].
On the other hand, the active T-PEMF had less impro-
vement on the UKU subscale of autonomic symptoms
compared to sham T-PEMF. It was especially the item of
diarrhoeathatresultedinthisdiﬀerence,withaneﬀectsizeof
−0.58. However, the eﬀect size of 0.09 on the total UKU-24
indicated no clinically signiﬁcant diﬀerence between active
and sham T-PEMF. In total, ﬁve patients dropped out of the
study: four patients during active T-PEMF and one patient
during sham T-PEMF. In other words, only 12.5% of the
initial 40 patients at baseline dropped out.
In the patient-reported WHO-5 well-being index quality
of life assessment, on which high scores signify better well-
being, the eﬀect size level was −0.48, indicating an advantage
of active T-PEMF over sham T-PEMF of a medium clinically
signiﬁcant magnitude. As discussed elsewhere in trials of
antidepressants, the eﬀect on quality-of-life measurements is
often of clinical signiﬁcance after a treatment period longer
than 5 weeks [26].
The self-reported HAM-D6-S was in this study found to
be as sensitive as the clinician-administrated HAM-D6.I n
our previous psychometric validation study of HAM-D6-S,
the use of item response theory models demonstrated that
the total score was suﬃcient [6].
In conclusion, this reanalysis of the T-PEMF study
[2], focussing on the pharmacopsychometric triangle with
its use of eﬀect size statistics and incorporating the self-
reported HAM-D6-S, has conﬁrmed the superiority of active
T-PEMF over sham T-PEMF in patients maintaining the
antidepressive medication they had been resistant to. In the
previous T-PEMF report, the mixed model (the random-
eﬀects regression model) was used for the intent-to-treat
approach [2], but in this revisited study, we have used a
conservative intent-to-treat approach by carrying forward
the last observation (LOCF). Even within this conservative
a p p r o a c h ,w ew e r ea b l et oc o n ﬁ r mt h es u p e r i o r i t yo fa c t i v e
T-PEMF over sham T-PEMF.
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